Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 2Neoplasms 2Wilms Tumor 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Death 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 16Carboplatin 15Bevacizumab 7Hyperthermic Intraperitoneal Chemotherapy 5Cisplatin 4Taxes 3Gemcitabine 3Cytoreduction Surgical Procedures 3Chemotherapy, Adjuvant 3oregovomab 2niraparib 2fluzoparib 2Topotecan 2ST 1481 2Neoadjuvant Therapy 2Methods 2Immunohistochemistry 2Ifosfamide 2Gene Expression Profiling 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Amplified Fragment Length Polymorphism Analysis 2rucaparib 1pembrolizumab 1paclitaxel poliglumex 1olaparib 1navicixizumab 1mirvetuximab soravtansine 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Fallopian Tube Neoplasms × Genes, p53 × Clear all
NCT02435186 2015-05-06

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 2 Unknown
100 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡